

# Luciano Mutti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3151103/luciano-mutti-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136  
papers

4,550  
citations

36  
h-index

64  
g-index

162  
ext. papers

5,251  
ext. citations

5.9  
avg, IF

5.11  
L-index

#	Paper	IF	Citations
136	CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e13	21.7	3
135	Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?. <i>Journal of Thoracic Oncology</i> , <b>2022</b> , 17, e10-e12	8.9	1
134	Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e221490	10.4	3
133	A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. <i>Cancers</i> , <b>2022</b> , 14, 2527	6.6	2
132	Abemaciclib for malignant pleural mesothelioma. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e237	21.7	0
131	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , <b>2021</b> , 11,	3	3
130	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e532	21.7	2
129	Is There Already a Need of Reckoning on Cancer Immunotherapy?. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 638279	5.6	3
128	Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
127	Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
126	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 684110	5.3	3
125	CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
124	A Glimpse in the Future of Malignant Mesothelioma Treatment.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 809337	5.6	1
123	Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1208	8.4	11
122	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, S100-S119	4.4	25
121	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	57
120	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 2391-2400	4.4	6

119	Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , <b>2020</b> , 57, 835-844	4.4	2
118	Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state. <i>Oncology Reports</i> , <b>2020</b> , 44, 2406-2418	3.5	3
117	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2020</b> , 58, 1-24	3	16
116	Tumour Treating Fields for mesothelioma. <i>Lancet Oncology</i> , <b>2020</b> , 21, e8	21.7	2
115	HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	44
114	Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report). <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 341	8.5	6
113	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , <b>2020</b> , 9,	7.9	17
112	P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 748	9.8	15
111	PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 5565-5577	5.6	12
110	Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	30
109	The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks. <i>Genes</i> , <b>2019</b> , 10,	4.2	18
108	The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies <b>2019</b> , 117-136		
107	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 89	5.7	4
106	What can independent research for mesothelioma achieve to treat this orphan disease?. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 719-732	5.9	2
105	Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 949	5.3	8
104	A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. <i>Cancer Research</i> , <b>2018</b> , 78, 5741-5753	10.1	19
103	Surgery for malignant pleural mesothelioma: an international guidelines review. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S285-S292	2.6	19
102	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	5

101	p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 282	8.5	7
100	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1269-1283	8.9	54
99	Anti-CTLA-4 therapy for malignant mesothelioma. <i>Immunotherapy</i> , <b>2017</b> , 9, 273-280	3.8	15
98	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. <i>Scientific Reports</i> , <b>2017</b> , 7, 3140	4.9	38
97	The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 119	8.3	18
96	Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 455-465	1.1	7
95	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S626-S627	8.9	3
94	Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. <i>Occupational and Environmental Medicine</i> , <b>2017</b> , 74, 456-463	2.1	5
93	Immunotherapy advances for mesothelioma treatment. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 799-814	3.5	10
92	Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 933-944	5.9	11
91	Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. <i>Genes and Cancer</i> , <b>2017</b> , 8, 438-452	2.9	13
90	Insight into glucocorticoid receptor signalling through interactome model analysis. <i>PLoS Computational Biology</i> , <b>2017</b> , 13, e1005825	5	5
89	Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178606	3.7	4
88	The role of microenvironment and immunity in drug response in leukemia. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2016</b> , 1863, 414-426	4.9	51
87	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. <i>Genes and Cancer</i> , <b>2016</b> , 7, 340-354	2.9	18
86	Targeting hypoxic response for cancer therapy. <i>Oncotarget</i> , <b>2016</b> , 7, 13464-78	3.3	73
85	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. <i>Oncotarget</i> , <b>2016</b> , 7, 34084-99	3.3	127
84	New standard for assessing asbestos exposure and its consequences?. <i>Occupational and Environmental Medicine</i> , <b>2016</b> , 73, 709-10	2.1	

83	Tremelimumab for the treatment of malignant mesothelioma. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1819-29	5.4	17
82	Expression status of candidate genes in mesothelioma tissues and cell lines. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2015</b> , 771, 6-12	3.3	19
81	Malignant pleural mesothelioma: new ideas needed. <i>Lung Cancer Management</i> , <b>2015</b> , 4, 201-203	2.6	2
80	The Expanded p53 Interactome as a Predictive Model for Cancer Therapy. <i>Genomics and Computational Biology</i> , <b>2015</b> , 1, 20		2
79	Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo. <i>Oncotarget</i> , <b>2015</b> , 6, 37471-85	3.3	23
78	A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1662-8	8.9	13
77	79 The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2014</b> , 83, S29-S30	5.9	3
76	MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. <i>PLoS ONE</i> , <b>2014</b> , 9, e85935	3.7	20
75	Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2013</b> , 1832, 2085-96	6.9	50
74	Therapies currently in Phase II trials for malignant pleural mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 1255-63	5.9	15
73	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 1104-1111	21.7	262
72	BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. <i>PLoS ONE</i> , <b>2013</b> , 8, e65489	3.7	12
71	PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. <i>Journal of Cellular and Molecular Medicine</i> , <b>2013</b> , 17, 233-41	5.6	28
70	Estrogen receptor $\beta$ activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. <i>Oncogenesis</i> , <b>2013</b> , 2, e72	6.6	30
69	Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. <i>PLoS ONE</i> , <b>2013</b> , 8, e58051	3.7	18
68	Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , <b>2012</b> , 6, 171-3		2
67	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 2983-92	7.5	25
66	Epigallocatechin-3-gallate induces mesothelioma cell death via H <sub>2</sub> O <sub>2</sub> -dependent T-type Ca <sup>2+</sup> channel opening. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 2667-78	5.6	32

65	Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 243-8	8.9	7
64	Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. <i>PLoS ONE</i> , <b>2012</b> , 7, e36856	3.7	35
63	Chemoprevention of asbestos-linked cancers: a systematic review. <i>Anticancer Research</i> , <b>2012</b> , 32, 1005-123	12	
62	Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , <b>2011</b> , 226, 2595-600	7	14
61	Estrogen receptor $\beta$ exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. <i>PLoS ONE</i> , <b>2010</b> , 5, e14110	3.7	48
60	Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma. <i>International Journal of Biological Markers</i> , <b>2010</b> , 25, 164-170	2.8	28
59	MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2010</b> , 42, 312-9	5.7	140
58	Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , <b>2010</b> , 35, 479-95	13.6	444
57	Translational therapies for malignant pleural mesothelioma. <i>Expert Review of Respiratory Medicine</i> , <b>2010</b> , 4, 249-60	3.8	7
56	Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 176-91	2.8	20
55	Will antiangiogenic agents be a future for mesothelioma therapy?. <i>Current Medicinal Chemistry</i> , <b>2010</b> , 17, 3069-79	4.3	2
54	In vitro and in vivo characterization of highly purified human mesothelioma derived cells. <i>BMC Cancer</i> , <b>2010</b> , 10, 54	4.8	22
53	Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. <i>International Journal of Biological Markers</i> , <b>2010</b> , 25, 164-70	2.8	18
52	Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1399-407	13.6	19
51	Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. <i>Cancer Research</i> , <b>2009</b> , 69, 4598-604	10.1	74
50	Malignant pleural mesothelioma: current treatments and emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , <b>2009</b> , 14, 423-37	3.7	29
49	Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2009</b> , 671, 76-83	3.3	15
48	Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. <i>Journal of Infection</i> , <b>2009</b> , 58, 53-60	18.9	29

47	In arrayed ranks: array technology in the study of mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 411-25	8.9	16
46	BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. <i>Oncogene</i> , <b>2008</b> , 27, 1189-97	9.2	128
45	Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. <i>Mutation Research - Reviews in Mutation Research</i> , <b>2008</b> , 658, 162-71	7	35
44	Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. <i>Mutation Research - Reviews in Mutation Research</i> , <b>2008</b> , 659, 126-36	7	50
43	Advances in the systemic therapy of malignant pleural mesothelioma. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 136-47		120
42	Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 541-8	12.9	59
41	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 601-9	4.4	30
40	The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma. <i>Oncology Reviews</i> , <b>2008</b> , 2, 61-65	4.3	3
39	Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 2739-43	7.5	45
38	Erionite and asbestos differently cause transformation of human mesothelial cells. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 12-20	7.5	41
37	Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 149-50	3.5	55
36	Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5942-51	12.9	81
35	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. <i>Thorax</i> , <b>2007</b> , 62, 690-5	7.3	40
34	Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5076-81	12.9	121
33	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , <b>2005</b> , 48, 429-34	5.9	47
32	New agents in the management of advanced mesothelioma. <i>Seminars in Oncology</i> , <b>2005</b> , 32, 336-50	5.5	35
31	SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. <i>Cancer Research</i> , <b>2005</b> , 65, 3049-52	10.1	80
30	SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. <i>Cancer Research</i> , <b>2005</b> , 65, 5256-62	10.1	74



29	A molecular epidemiology case control study on pleural malignant mesothelioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1741-6	4	26
28	Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 835-42	6.1	48
27	New Target Therapies for Malignant Mesothelioma <b>2005</b> , 765-777		
26	Growth Factors and Malignant Mesothelioma <b>2005</b> , 112-123		
25	Transforming growth factor- $\beta$ released by PPD-presenting malignant mesothelioma cells inhibits interferon- $\beta$ synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , <b>2003</b> , 11, 161	4.4	0
24	Simian virus 40 and malignant mesothelioma (Review) <b>2003</b> , 22, 187		2
23	SV40 and human brain tumors. <i>International Journal of Cancer</i> , <b>2003</b> , 106, 140-2; author reply 143-5	7.5	23
22	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , <b>2003</b> , 11, 161-7	4.4	4
21	Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. <i>Journal of Cellular Physiology</i> , <b>2002</b> , 193, 37-41	7	6
20	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. <i>Journal of Pathology</i> , <b>2002</b> , 197, 218-23	9.4	21
19	Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. <i>British Journal of Cancer</i> , <b>2002</b> , 86, 979-82	8.7	74
18	The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2002</b> , 26, 189-93	5.7	62
17	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , <b>2002</b> , 38, 159-62	5.9	6
16	High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. <i>Cancer Research</i> , <b>2002</b> , 62, 5418-9	10.1	23
15	Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. <i>Journal of Pathology</i> , <b>2001</b> , 193, 468-75	9.4	290
14	Association of SV40 with human tumours. <i>Seminars in Cancer Biology</i> , <b>2001</b> , 11, 49-61	12.7	90
13	SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 12032-7	11.5	126
12	Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. <i>Lung Cancer</i> , <b>2001</b> , 31, 303-10	5.9	69



11	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. <i>Journal of Cellular Physiology</i> , <b>2000</b> , 185, 126-34	7	13
10	Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 29, 173-9	5	53
9	Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. <i>Human Pathology</i> , <b>2000</b> , 31, 1341-1345	3.7	6
8	Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. <i>Anticancer Research</i> , <b>2000</b> , 20, 891-4	2.3	26
7	Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. <i>European Respiratory Journal</i> , <b>1999</b> , 13, 527-34	13.6	52
6	Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. <i>International Journal of Cancer</i> , <b>1998</b> , 78, 740-9	7.5	25
5	The detection of simian virus 40 in human tumors by polymerase chain reaction. <i>Monaldi Archives for Chest Disease</i> , <b>1998</b> , 53, 202-10	2.7	9
4	Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. <i>Developments in Biological Standardization</i> , <b>1998</b> , 94, 33-40		5
3	Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. <i>Developments in Biological Standardization</i> , <b>1998</b> , 94, 47-53		7
2	Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Respiratory Journal</i> , <b>1995</b> , 8, 1566-71	13.6	8
1	Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. <i>Pathologica</i> , <b>1993</b> , 85, 725-8	1.9	6